Free Trial

Harmony Biosciences Q2 2023 Earnings Report

Harmony Biosciences logo
$32.42 -0.77 (-2.32%)
As of 04:00 PM Eastern

Harmony Biosciences EPS Results

Actual EPS
$0.56
Consensus EPS
$0.62
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Harmony Biosciences Revenue Results

Actual Revenue
$134.22 million
Expected Revenue
$139.79 million
Beat/Miss
Missed by -$5.57 million
YoY Revenue Growth
N/A

Harmony Biosciences Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Remove Ads

Harmony Biosciences Earnings Headlines

Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
See More Harmony Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Harmony Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harmony Biosciences and other key companies, straight to your email.

About Harmony Biosciences

Harmony Biosciences (NASDAQ:HRMY), a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

View Harmony Biosciences Profile

More Earnings Resources from MarketBeat